Early treatment of candidemia in adults: A review

Luis Ostrosky-Zeichner, Bart Jan Kullberg, Eric J. Bow, Susan Hadley, Cristbal Len, Marcio Nucci, Thomas F. Patterson, John R. Perfect

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations

Abstract

Invasive candidiasis is associated with high mortality, particularly in adults. Retrospective studies show that shorter times to treatment are correlated with a lower risk of death. A number of factors can be used to predict which patients would benefit from antifungal prophylaxis or early (pre-emptive or empirical) therapy. Detection of the fungal cell wall component (1→3)-β-D-glucan (BDG) shows promise as an early biomarker of invasive fungal infection and may be useful in identifying patients who would benefit from early antifungal treatment. To date, no consistent early treatment strategy has evolved. Proof-of-concept studies are needed to assess the role of pre-emptive and empirical therapy in ICU patients and the relevance of BDG as an early marker of infection.

Original languageEnglish (US)
Pages (from-to)113-120
Number of pages8
JournalMedical mycology
Volume49
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • Antifungals
  • candidemia
  • empirical therapy
  • invasive candidiasis
  • pre-emptive therapy

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Early treatment of candidemia in adults: A review'. Together they form a unique fingerprint.

Cite this